

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>A61K 39/02, A01N 63/00</b>		A1	(11) International Publication Number: <b>WO 92/12732</b> (43) International Publication Date: 6 August 1992 (06.08.92)
(21) International Application Number: PCT/US92/00166 (22) International Filing Date: 10 January 1992 (10.01.92)  (30) Priority data: 647,157 29 January 1991 (29.01.91) US		(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, RU, SD, SE, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent).	
(71) Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street S.E., Minneapolis, MN 55455 (US). (72) Inventors: NAGARAJA, Kakambi, V ; 2235 Milton Street North, St Paul, MN 55113 (US). EMERY, Daryll ; 10127 - 170th Street, Hugo, MN 55038 (US). (74) Agent: HAMRE, Curtis, B.; Merchant, Gould, Smith, Edell, Welter & Schmidt, 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US).		Published <i>With international search report.</i>	
(54) Title: LIVE VACCINE AGAINST COLIBACILLOSIS			
(57) Abstract			
<p>A vaccine for the immunization of domestic fowl, such as turkeys and chickens, against <i>E. coli</i> infections (Colibacillosis) is disclosed which contains an effective amount of a live temperature sensitive mutant of <i>E. coli</i> dispersed in a physiologically acceptable, non-toxic liquid vehicle. The <i>E. coli</i> mutant disclosed exhibits growth at 32 °C but not at 41 °C and has a reversion frequency of less than about 1 x 10<sup>-8</sup>.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		

LIVE VACCINE AGAINST COLIBACILLOSISField of the Invention

5 The present invention relates to a live mutant  
E. coli vaccine.

Background of the Invention

10 Infections with Escherichia coli, commonly referred to as colibacillosis, are a major cause of death among birds in the poultry industry. Outbreaks of colibacillosis have been reported in ducks, chickens, and turkeys.

15 E. coli is subdivided into serological groups based on the antigenic differences of the lipopolysaccharide somatic O, flagellar H and K capsular antigens. More than 170 different O antigens of E. coli have been identified by specific agglutination reactions. In addition, approximately 56 H antigens and over 80 K 20 antigens have been described. Relatively few serological groups of E. coli have been identified in disease outbreaks of colibacillosis. The serological groups usually responsible are 01a:K1; 02a:K1; and 078:K80. Other serological groups less frequently incriminated in 25 disease outbreaks are 03, 06, 08, 011, 015, 022, 055, 074, 088, 095, and 0109.

30 E. coli is a normal inhabitant of the intestinal tract of most mammals and birds. Birds are continuously exposed to E. coli through contaminated feces, water, feed and other aspects of their environment. Virulent and avirulent strains of E. coli shed into the poultry house environment can survive in dust for periods exceeding 32 weeks in an atmosphere of low humidity. The high concentration of E. coli in the poultry house environment, 35 together with the ability of these bacteria to survive for long periods of time, results in the continuous exposure of birds to potential pathogens.

E. coli is an opportunistic organism causing disease in an already predisposed or immunosuppressed

host. Birds become extremely susceptible to respiratory infections of E. coli during primary infections of New castle disease, Mycoplasmosis and Infectious bronchitis. The respiratory tract is the predominant route of exposure 5 leading to clinical infections of E. coli. This is primarily due to inhalation of contaminated dust during periods of low humidity, crowding of birds, and reduced ventilation with excess accumulation of ammonia.

Two forms of E. coli disease are recognized in 10 the poultry industry (i.e., systemic colibacillosis and enteric colibacillosis). However, poultry are normally only affected by the systemic form of colibacillosis, typically after a previous respiratory disease. In 15 systemic colibacillosis, the invading organism passes through the mucosa of the alimentary or respiratory tract and enters the blood stream. This invasion may result in a generalized infection (colisepticaemia) or localized infection.

Respiratory distress and sneezing associated with 20 lesions of the lower respiratory tract are characteristic of colibacillosis. Most deaths occur during the first five days of the disease. The disease has been associated with a number of pathological conditions: Fibrinous pericarditis; perihepatitis; coligranuloma; salpingitis; 25 synovitis; and air-sacculitis.

The control of many bacterial diseases in chickens and turkeys is often accomplished by immunologic intervention with protective vaccines. Both live and inactivated vaccines have been employed in chicken and 30 turkey populations. Attenuated viable organisms have been employed for inducing protection against Mycoplasma gallisepticum, Pasteurella multocida, and Alcaligenes faecalis [H. E. Adler et al., Am. J. Vet. Res., 21, 482-485 (1960); H. E. Adler et al., Avian Dis., 14, 763-769 35 (1970); I. Hertman et al., Avian Dis., 24, 863-869 (1979); D. S. Burke et al., Avian Dis., 24, 726-733 (1980); A. Michael et al., Avian Dis., 24, 870-877 (1979); A. Michael

et al., Avian Dis., 24, 878-884 (1979); J. T. Rice et al., Abstr. in Poultry Sci., 55, 1605 (1976); S. R. Coates et al., Poultry Sci., 56, 273-276 (1977)]. See also United States Patent No. 4,379,140. These attenuated live vaccines have been successfully applied in the drinking water and protect turkeys against intravenous challenge with the homologous serotypes. Inactivated vaccines or bacterins utilizing various adjuvants have been very successful, particularly against such diseases as fowl cholera (P. multocida) and infectious coryza (H. paragallinarum). Monovalent bacterins have been shown to protect against homologous challenge and possibly against heterologous antigens as well [S. R. Coates et al., supra (1977); B. W. Bierer, Poultry Sci., 48, 633-666 (1969); A. Michael et al., Refuah Vet., 33, 117-121 (1976)]. Inactivated E. coli vaccines have been shown to provide protection against systemic challenge, but failed to protect when birds were challenged orally or by the respiratory aerosol method [J. R. Deb et al., Res. Vet. Sci., 24, 308-313 (1978); L. H. Arp, Avian Dis., 24, 808-814 (1980); A. Zanella et al., in Developments in Biological Standardization, Y. Moreau and W. Hennessen, eds., S. Krager, Basel., Vol. 51, pp. 19-32 (1982); J. R. Deb et al., Res. Vet. Sci., 20, 131-138 (1976)].

Immunologic intervention with protective vaccines for the control of colibacillosis in the avian species has met with limited success. The problems in controlling this disease lie partly in determining the factors affecting virulence of strains, colonization, invasiveness, and toxin production [M. M. Levine, in Bacterial Vaccines, R. Germanier, ed., Academic Press, Orlando, Florida, pp. 187-235 (1984); M. M. Levine et al., Microbio. Rev., 47, 510-550 (1983)].

An oral or aerosol vaccine against colibacillosis has several advantages over parental vaccines, including the ease of administration and the lack of adverse side reactions. The ability to colonize the upper nasal mucosa

would profoundly influence the immunogenic efficiency of an aerosol vaccine. Since the respiratory tract is the primary entrance site for these pathogenic E. coli organisms, direct stimulation of local secretory 5 antibodies at the portal of entry can enhance immunization against infection in several ways: it would prevent adhesion and colonization of infecting organisms; neutralize toxins; and may have a bactericidal effect, thus inhibiting the systemic entry of E. coli. See S. H. 10 Parry et al., in The Virulence of Escherichia coli, M. Sussman, ed., The Society for General Microbiology, Academic Press, pp. 79-153 (1985); J. H. Darbyshire, in Avian Immunology, A. Toivanen and P. Toivanen, eds., CRC Press, Inc., Vol. 11, pp. 129-161 (1987); J. H. Darbyshire 15 et al., Res. Vet. Sci., 38, 14-21 (1985); J. B. Kaper et al., Vaccine, 6, 197-199 (1987); M. M. Levine et al., Infect. Immun., 23, 729-736 (1979)]. A greater local immune response can be induced using live vaccines as opposed to an inactivated, killed vaccine. This may be 20 due to antigens present on live bacteria that may be absent or altered on inactivated, killed bacteria. However, live vaccines employing mutant strains of bacteria are subject to reversion, thereby resulting in loss of the desired immunologic characteristic.

25 Because of modern high-density confinement rearing practices and the ubiquitous nature of colibacillosis, it has been extremely difficult to control. The control and prevention of avian colibacillosis has, to a large extent, depended upon 30 proper management practices such as use of pelletized feed, free of fecal contamination; the control of rodent populations; proper ventilation; the use of noncontaminated drinking water; and the control of fecal contamination of hatching eggs. Accordingly, there is a 35 need for a stable live vaccine effective to immunize domestic fowl such as turkeys and chickens against colibacillosis.

Summary of the Invention

The present invention is directed to a vaccine which is effective to immunize domestic fowl such as turkeys, chickens, and ducks against colibacillosis. The vaccine comprises an effective amount of a stable live temperature sensitive mutant of Escherichia coli dispersed in a physiologically acceptable non-toxic vehicle. The mutant bacteria is characterized by growth at 32°C but not at 41°C and a reversion frequency of less than about  $1 \times 10^{-8}$ , and most preferably less than  $1 \times 10^{-9}$ . Intranasal vaccination of turkeys with a single dose of a suspension of about  $10^7$  CFU (colony forming units) of the temperature sensitive mutant in 0.1 ml normal saline provides 100% protection against infection due to a virulent strain of E. coli.

Preferred embodiments of the invention employ temperature sensitive mutants of E. coli serotypes 078, 01a, and 02a. A preferred vaccine includes suspending the temperature sensitive mutant in a physiologically acceptable non-toxic liquid vehicle to yield an oral or aerosol vaccine. A preferred vaccine is capable of colonizing the upper nasal mucosa of a domestic fowl for at least 20 days post inoculation.

The present invention further provides a method for obtaining a temperature sensitive mutant of Escherichia coli capable of colonizing the nasal mucosa of a domestic fowl, such as a turkey, chicken, or duck. The preferred method includes the steps of (a) treating a culture of Escherichia coli with amounts of a mutagen and a protein synthesis inhibitor, sufficient to maximize mutation and minimize reversion frequency; and (b) selecting culture mutants exhibiting growth at 32°C but not at 41°C and having a reversion frequency of less than  $1 \times 10^{-8}$ , and preferably less than  $1 \times 10^{-9}$ . Preferably, the culture is treated with about 1000 µg/ml of the mutagen N-methyl-N-nitro-N-nitrosoguanidine.

Detailed Description of the Invention

The immunogenic bacteria employed as the active component of the present vaccines is a stable live 5 temperature sensitive mutant of Escherichia coli exhibiting the following properties: (1) inhibited growth at the internal body temperature of poultry (41°C); (2) avirulence to poultry when administered intravenously; and (3) colonizing ability for extended periods of time at 10 the cooler tissues of the upper nasal mucosa of poultry. The ts-mutant produced according to the present invention was able to grow at 32°C and was unable to grow at 41°C.

While E. coli is a normal inhabitant of the intestinal tract of most mammals and birds, most diseases 15 and particularly colibacillosis in poultry is associated with relatively few serological groups--for example, 01a, 02a, and 078. Serotype 078 is the serotype isolated most frequently in outbreaks of colibacillosis. It will be understood that the parent strain of E. coli used to 20 select a mutant for a vaccine of the present invention will be one of the virulent colibacillosis producing strains. As used herein, the term "stable" describes mutant resistance to reversion of one or more of the above selected mutation characteristics. In general, "mutation" 25 refers to a sudden heritable change in the phenotype of an organism which can be spontaneous or induced by known mutagenic agents, including radiation and various chemicals. Among the useful chemical mutagens for the present invention are N-methyl-N-nitro-N-nitrosoguanidine 30 (MNNG), ethyl methane sulfonate (EMS), nitrous acid, or the like. A preferred mutagen is MNNG used in amounts from about 10 µg/ml to 1000 µg/ml, most preferably in an amount of about 1000 µg/ml.

According to the present invention, in order to 35 maximize mutagenesis and minimize reversion of the mutants obtained, a protein synthesis inhibitor is employed, in addition to the above-mentioned mutagen. Protein

synthesis inhibitors useful in the present invention include chloramphenicol, actinomycin, Spectinomycin, Lincomycin, Erythromycin, or the like. A preferred protein synthesis inhibitor is chloramphenicol.

5 In a preferred embodiment, to maximize mutation and minimize reversion, amounts of chloramphenicol from about 10 to 50  $\mu\text{g}/\text{ml}$ , preferably 25  $\mu\text{g}/\text{ml}$  to 50  $\mu\text{g}/\text{ml}$ , and most preferably in an amount of about 25  $\mu\text{g}/\text{ml}$  are used. The use of a known mutant such as MNNG, in  
10 combination with chloramphenicol, unexpectedly produces mutants with reversion frequencies of less than  $1 \times 10^{-9}$ . These mutants have been observed to remain stable for up to 32 passages or subcultures.

To use the ts-mutant of the present invention as  
15 a vaccine agent, cells of the selected mutant are combined with a suitable physiologically acceptable non-toxic liquid vehicle such as a saline solution having a concentration of up to at least 0.85%. The amount of cells included in a given unit dosage form of vaccine can  
20 vary widely, and depends upon factors such as the age, weight and physical condition of the subject considered for vaccination. Such factors can be readily determined by the clinician or veterinarian employing animal models or other test systems which are well known to the art. A  
25 unit dose of the vaccine can be administered parenterally, e.g., by subcutaneous or by intramuscular injection; however, oral or aerosol delivery is preferred. The preferred vaccine may be administered by mixing the ts-mutant strain in the birds drinking water and making the  
30 water available to the birds for 4 to 24 hours. Alternatively, the vaccine may be administered intranasally by dropping the nares or as an aerosol. Exemplary titers of ts-E. coli mutant cells in an effective vaccine will range from about  $1 \times 10^6$  to  $1 \times 10^{11}$   
35 colony forming units/ml, preferably from about  $1 \times 10^7$  to  $1 \times 10^{10}$  CFU/ml.

As described in the Examples below, when the ts-E. coli mutant vaccine was administered to turkeys intravenously, no mortality was exhibited, unlike turkeys given the parent virulent non-mutant by the same route.

- 5 All turkeys given the parent non-mutant died within one week post inoculation.

Extensive colonization of the nasal mucosa was seen with the ts-E. coli mutant strain. There was minimal colonization of the mutant in the trachea. Colonization 10 of the upper nasal mucosa with the mutant lasted 20 days. Turkeys challenged intranasally with virulent E. coli 078 showed a dramatic decrease in the ability of this pathogenic serotype to colonize the nasal mucosa.

15

Brief Description of the Drawings



Figure 1 is a graphic description of nasal colonization of temperature sensitive mutant, non-mutant E. coli 078 and control (non-vaccinated/challenged). The mutant and non-mutant groups were intranasally inoculated 20 at two weeks of age. The control was non-inoculated/challenged. Each sampling time represents the mean colony forming units/group taken intranasally at four-day intervals. Twenty days post inoculation, all groups were challenged intranasally with  $2 \times 10^6$  CFU/bird 25 with a nalidixic acid resistant strain of E. coli 078 (  ts-mutant;  non-mutant;  control (non-V/CH) ).

Figure 2 is a graphic description of tracheal colonization of temperature sensitive mutant, non-mutant 30 E. coli 078 and control (non-vaccinated/challenged). The mutant and non-mutant groups were intranasally inoculated at two weeks of age. The control was non-inoculated/challenged. Each sampling time represents the mean colony forming units/group taken intranasally at 35 four-day intervals. Twenty days post inoculation, all groups were challenged intranasally with  $2 \times 10^6$  CFU/bird

with a nalidixic acid resistant strain of E. coli 078 (████ ts-mutant; █████ non-mutant; █████ control (non-V/CH)).

Figure 3 is a bacterial growth curve of mutant  
5 and non-mutant E. coli 078 at 32°C and 41°C.

The following non-limiting Examples are  
illustrative of the present invention.

10

Example 1

Live Mutant 078 E. coli Vaccine:  
Preparation and Evaluation of Efficacy in Turkeys

A. Bacteria. A field isolate of E. coli (serotype 078:K80) was used for the mutagenesis. For challenge, a parent virulent non-mutant strain of the same serotype was used, but was nalidixic acid (Sigma Chemical Co., St. Louis, Missouri) resistant. Bacteria resistant to nalidixic acid were obtained by spreading 1 ml of a 12 hour broth culture, containing  $10^8$  viable organisms per ml over the surface of a MacConkey agar (Difco) plate containing 500 ng/ml nalidixic acid. The plates were incubated at 37°C for 24 hours and colonies that grew were cloned by plating on MacConkey's agar containing 100 ng/ml nalidixic acid.

B. Mutation and selection of ts-mutant. The induction of the ts-mutant of E. coli was done by first establishing a culture in exponential growth phase. One milliliter of a 12 hour culture, grown at 37°C in triptic soy broth (TSB) was transferred to 20 ml TSB prewarmed to 37°C with continuous shaking for 5 hours. The culture was centrifuged at 15,000 x g for 10 minutes and resuspended in 20 ml of TSB (pH 7.2) containing a final concentration of 1000 µg/ml of N-methyl-N-nitro-N-nitrosoguanidine (Sigma), prewarmed to 32°C. The mixture was then incubated with continuous shaking for 5 minutes at 32°C,

at which time chloramphenicol (Sigma) was added to give a concentration of 25 µg/ml. The mixture was then incubated for an additional 15 minutes. After this period of incubation, an equal volume of cold (4°C) phosphate buffered saline (PBS) pH 7.2 was added to the mixture and centrifuged at 15,000 x g for 10 minutes. This step was repeated two more times with an equal volume of PBS to remove all residual MNNG.

Bacteria exposed to MNNG were serially diluted 10-fold and plated onto MacConkey agar plates, incubated at 32°C for 48 hours. Plates having 50-150 colonies were replica plated using a replicate colony transfer pad (FMC Bio Products, Rockland, Maine) onto two other MacConkey agar plates, one was incubated at 32°C and the other at 41°C. Mutants were selected based on smaller colony morphology than the parental strain and inhibited growth at 41°C.

C. Reversion frequency and rate of growth. The reversion frequency and rate of growth of selected ts-mutants at permissive and restricted temperatures were determined and compared to that of the non-parent mutant *E. coli*. The reversion frequency was calculated by dividing the number of colony forming units at 41°C by the number of colony forming units at 32°C (CFU at 41°C/CFU at 32°C). Stability against reversion was tested by culturing 12 successive 48 hour back passages in TSB at permissive and restricted temperatures.

Eight ts-mutants were selected after screening several thousand colonies. Mutants were selected based on smaller colony morphology than the parent strain and inhibited growth at 41°C. The reversion frequency of these mutants ranged from  $10^{-3}$  to  $10^{-9}$ , as indicated in Table 1 below.

Table 1  
REVERSION FREQUENCY OF SELECTED TS-MUTANTS

MUTANT	CFU AFTER 12, 48HR BACK PASSAGES		REVERSION FREQUENCY * CFU AT 41C/CFU AT 32C
	41C	32C	
ts-1	2.2 X 10 <sup>6</sup>	5.0 X 10 <sup>9</sup>	0.4 X 10 <sup>-3</sup>
ts-2	2.0 X 10 <sup>1</sup>	2.2 X 10 <sup>10</sup>	0.9 X 10 <sup>-9</sup>
ts-3	1.6 X 10 <sup>5</sup>	1.3 X 10 <sup>9</sup>	1.2 X 10 <sup>-4</sup>
ts-4	2.0 X 10 <sup>4</sup>	3.7 X 10 <sup>9</sup>	0.5 X 10 <sup>-5</sup>
ts-5	8.1 X 10 <sup>2</sup>	5.3 X 10 <sup>10</sup>	1.5 X 10 <sup>-8</sup>
ts-6	1.0 X 10 <sup>6</sup>	8.3 X 10 <sup>9</sup>	0.1 X 10 <sup>-3</sup>
ts-7	1.5 X 10 <sup>2</sup>	6.1 X 10 <sup>10</sup>	0.2 X 10 <sup>-8</sup>
ts-8	8.5 X 10 <sup>3</sup>	9.1 X 10 <sup>9</sup>	0.9 X 10 <sup>-6</sup>

\* CFU = COLONY FORMING UNITS

**SUBSTITUTE SHEET**

The mutant with the lower reversion frequency of  $10^{-9}$  was selected as the vaccine strain to be evaluated. The strain has been deposited with the American Type Culture Collection, Rockville, Maryland, (ATCC No. 55141, 5 deposit date January 21, 1991). All other mutants were lyophilized and stored for future evaluation.

The mutant with the lowest reversion frequency was selected and its rate of growth at 32°C and 41°C was compared to the parent non-mutant E. coli. The parent 10 non-mutant and mutant E. coli were inoculated into TSB pre-warmed to 32°C (mutant) and 41°C (non-mutant) for an incubation period of 6 hours. The cultures were adjusted to 90% T at a wavelength of 540 nm. One milliliter of each culture was transferred to 20 ml TSB. Both the 15 mutant and non-mutant were incubated at 41°C and 32°C. Standard plated counts were done in duplicate for a period of 12 hours. The growth curve of the mutant at 32°C and 41°C was determined and compared to that of the non-mutant E. coli (see Table 2 below).

TABLE 2

TWELVE HOUR GROWTH CURVE OF MUTANT AND NON-MUTANT  
E. COLI 078 INCUBATED AT 32°C AND 41°C<sup>A</sup>

## AVERAGE OF DUPLICATE PLATE COUNTS

HOUR	MUTANT 32°C	MUTANT 41°C	NON-MUTANT 32°C	NON-MUTANT 41°C
1	17 X 10 <sup>3</sup>	0	18 X 10 <sup>3</sup>	17 X 10 <sup>3</sup>
2	19 X 10 <sup>3</sup>	0	2.0 X 10 <sup>4</sup>	18 X 10 <sup>4</sup>
3	49 X 10 <sup>3</sup>	0	5.0 X 10 <sup>5</sup>	42 X 10 <sup>5</sup>
4	80 X 10 <sup>3</sup>	0	56 X 10 <sup>6</sup>	65 X 10 <sup>6</sup>
5	22 X 10 <sup>5</sup>	0	24 X 10 <sup>7</sup>	51 X 10 <sup>7</sup>
6	52 X 10 <sup>5</sup>	0	18 X 10 <sup>8</sup>	15 X 10 <sup>8</sup>
7	49 X 10 <sup>6</sup>	0	10 X 10 <sup>9</sup>	14 X 10 <sup>9</sup>
8	20 X 10 <sup>7</sup>	0	52 X 10 <sup>9</sup>	48 X 10 <sup>9</sup>
9	40 X 10 <sup>7</sup>	0	2.6 X 10 <sup>10</sup>	2.5 X 10 <sup>10</sup>
10	78 X 10 <sup>7</sup>	0	3.3 X 10 <sup>10</sup>	2.2 X 10 <sup>10</sup>
11	97 X 10 <sup>7</sup>	0	2.6 X 10 <sup>10</sup>	3.4 X 10 <sup>10</sup>
12	1.4 X 10 <sup>8</sup>	0	1.2 X 10 <sup>10</sup>	3.0 X 10 <sup>10</sup>

<sup>A</sup>SAMPLES WERE TAKEN FROM EACH GROUP AT ONE HOUR INTERVALS  
AND PLATED IN DUPLICATE ON EOSIN METHYLENE BLUE AGAR

The growth curve of the mutant strain at 32°C and 41°C compared to that of the parent non-mutant E. coli is shown in Figure 3. As indicated in Figure 3, the mutant was able to grow at 32°C but unable to grow at 41°C.

5           The parent non-mutant grew equally well at both temperatures. There was a three-log difference in growth of the mutant at 32°C compared to that of the parent non-mutant at 32°C and 41°C for the duration of the growth curve. A mutant with a reduced growth rate able to  
10       colonize the upper nasal mucosa was selected based on the belief that the mutant would not be so invasive as to take over the immune system, causing stress and predisposing the bird to other infectious agents.

15       D. Morphological and biochemical characteristics of the mutant and parent non-mutant strains. Colony morphology and hemolytic characteristics of the mutant and parent non-mutant E. coli were determined on blood agar plates, incubated at appropriate  
20       temperatures for a period of 24 hours.

To determine if any biochemical differences existed between the mutant and parent non-mutant, biochemical testing was done at 32°C (mutant) and 41°C (non-mutant). Biochemical reactions were recorded  
25       positive or negative after 24 hours of incubation (see Table 3 below).

TABLE 3

BIOCHEMICAL CHARACTERISTICS OF THE MUTANT  
AND NON-MUTANT E. COLI

TEST	MUTANT	NON-MUTANT
ARGININE DIHYDROLASE	-	-
LYSINE DECARBOXYLASE	+	+
ORNITHINE DECARBOXYLASE	+	+
CITRATE	-	-
HYDROGEN SULFIDE	-	-
UREA HYDROLYSIS	-	-
TRYPTOPHANE DEAMINASE	-	-
O-NITROENYL-B-d-GALACTOSIDE	+	+
INDOLE	+	+
VOGES-PROSKAUER	-	-
GELATIN HYDROLYSIS	-	-
GLUCOSE	+	+
ACID	+	+
GAS	+	+
LACTOSE	+	+
MANNITOL	+	+
INOSITOL	-	-
SORBITOL	+	+
RHAMNOSE	+	+
SUCROSE	-	-
MELIBIOSE	+	+
AMYGDALIN	-	-
ARABINOSE	+	+
OXIDASE	-	-
MOTILITY	+	+
HEMOLYSIS	-	-

## KEY

+
 POSITIVE WITHIN 24HR INCUBATION  
 -
 NO REACTION

As seen in Table 3, there was no difference in morphological and biochemical properties between the mutant and parent non-mutant E. coli as demonstrated from the various biochemicals tested.

5 Colonies of the mutant and parent non-mutant appeared smooth with entire margins, showing no hemolysis when grown on blood agar plates. The only morphological difference seen between the mutant and non-mutant was the smaller colony size of the mutant, probably due to the  
10 slower growth rate of the mutant strain.

E. Test for pathogenicity. To determine if the mutant was pathogenic to turkeys, 16-week old turkeys were equally divided into two groups. Both groups were exposed  
15 intravenously with 1 mm of either the mutant or parent non-mutant culture whose pathogenicity to turkeys was established in our laboratory at a concentration of  $10^9$  CFU/ml in saline. Pathogenicity was determined by the time of death of birds in both groups. Birds found dead  
20 during the period of observation were necropsied and bacteriological examination of the heart, liver and hock joints was done.

The pathogenicity of the mutant was compared to parent virulent non-mutant strain 078, as indicated in  
25 Table 4 below. All birds given the virulent 078 died within one week post exposure. No deaths were seen with the infected mutant group. All dead birds of the virulent group were necropsied at the time of death and examined for gross signs of infection. E. coli was isolated from  
30 the heart, liver and hock joints from all birds infected with the virulent strain. All birds appeared healthy in the mutant group and were necropsied one week post-exposure. There were no signs of infection and all cultures were negative for E. coli.

TABLE 4

ISOLATION OF MUTANT AND NON-MUTANT E. COLI FROM  
THE LIVER, HEART, AND HOCK JOINT.<sup>A</sup>

ISOLATION OF MUTANT E. COLI <sup>C</sup> BIRDS NECROPSIED AT 7 DAYS POST INOCULATION					ISOLATION OF NON-MUTANT E. COLI <sup>B</sup> AT TIME OF DEATH			
BIRD	DEAD	LIVER	HEART	HOCK	DEAD	LIVER	HEART	HOCK
1	0	0	0	0	24hr	+	+	+
2	0	0	0	0	24hr	+	+	+
3	0	0	0	0	48hr	+	+	+
5	0	0	0	0	48hr	+	+	+
6	0	0	0	0	72hr	+	+	+
7	0	0	0	0	96hr	+	+	+
8	0	0	0	0	96hr	+	+	+

<sup>A</sup> THE MUTANT AND NON-MUTANT GROUPS WERE INTRAVENOUSLY  
INOCULATED WITH  $1 \times 10^9$  COLONY FORMING UNITS/BIRD.<sup>B</sup> SAMPLES FROM THE NON-MUTANT GROUP WERE TAKEN AT TIME OF  
DEATH.<sup>C</sup> SAMPLES FROM THE MUTANT GROUP WERE TAKEN 7 DAYS POST  
INOCULATION.

F. Vaccination. Sixty turkeys from a commercial hatchery were raised in isolation from one day of age. At two weeks of age, birds were equally divided into three groups. Each group of birds was housed 5 separately in an isolation facility. In group 1, the mutant was inoculated intranasally into 20 two-week old turkeys. Each bird received 0.1 ml saline containing  $10^7$  CFU/ml.

10 G. Nasal and tracheal colonization. Swabs were taken from the internal nares through the palatine cleft and from the lower trachea prior to exposure from all birds to ascertain pre-exposure status. Samples were taken from all birds at 4-day intervals post exposure to 15 examine the degree of colonization of the mutant strain compared with the virulent strain. The second group was intranasally inoculated with the virulent 078 of equal concentration ( $10^7$  CFU/ml). Twenty birds in group 3 were used as uninoculated controls. Swabs were streaked 20 directly onto EMB agar plates and incubated at 32°C and 41°C for 48 hours. The mutant strain was identified by its impaired growth at 41°C compared to its growth at 32°C.

The degree of colonization of the trachea and 25 nasal mucosa of the mutant, non-mutant and control (non-vaccinated/challenged) are summarized in Figures 1 and 2. Extensive colonization of the nasal mucosa was seen with the mutant strain, with slight colonization of the lower trachea. The non-mutant colonized both the nasal and 30 tracheal mucosa, with greater affinity for the lower trachea. Four days post-vaccination, colonization of the nasal mucosa with the mutant was significantly lower than with the non-mutant, possibly due to the slower growth rate of the mutant. Colonization with the mutant in the 35 nasal mucosa increased dramatically 8 days post vaccination and remained at a higher level than with the non-mutant up to the period of challenge. Slight

colonization with the mutant was seen in the trachea but was not much greater than with the control.

The non-mutant extensively colonized both the nasal and tracheal mucosa but the degree of colonization 5 predominated in the lower trachea. Colonization of the mutant and non-mutant in the nasal and tracheal mucosa lasted 3 weeks.

H. Challenge studies. Twenty days post 10 exposure to the mutant and parent virulent non-mutant strain of E. coli, turkeys in all three groups were challenged intranasally with a Nalidixic acid resistant virulent strain of E. coli 078. Each bird was inoculated with 0.2 ml of saline containing  $10^7$  CFU/ml. Seven days 15 post-challenge, swabs were taken from the internal nares and lower trachea from all birds in each group. Swabs were then streaked onto MacConkey agar plates containing 100  $\mu\text{g}/\text{ml}$  Nalidixic acid incubated at 32°C and 41°C for 48 hours, as indicated in Table 5 below.

TABLE 5

NASAL AND TRACHEAL COLONY FORMING UNITS IN MUTANT, NON-MUTANT  
AND CONTROL GROUPS 7 DAYS POST CHALLENGE<sup>A</sup>

<u>NASAL<sup>B</sup></u>			<u>TRACHEAL<sup>B</sup></u>		
Mutant	Non Mutant	Control	Mutant	Non Mutant	Control
0	0	>300	0	79	>300
0	3	>300	0	4	>300
0	2	296	0	0	>300
0	1	>300	0	5	157
0	0	194	2	1	190
2	0	169	0	150	135
0	3	>300	0	0	>300
0	2	219	0	49	174
0	1		0		
0	0		0		
0	0		0		
0	0		0		
0.17	1.0	260.0 $\bar{x}$ CFU <sup>C</sup>	0.16	36.0	232.0 $\bar{x}$ CFU <sup>C</sup>

<sup>A</sup> TWENTY DAYS POST INOCULATION ALL GROUPS WERE INTRANASALLY CHALLENGED WITH  $2 \times 10^6$  CFU/BIRD WITH A NALIDIXIC ACID RESISTANT STRAIN OF E. COLI 078.

<sup>B</sup> SAMPLES WERE TAKEN INTRANASALLY AND INTRATRACHEALLY 7 DAYS POST CHALLENGE.

<sup>C</sup>  $\bar{x}$  CFU = MEAN COLONY FORMING UNITS.

Challenge was 20 days post vaccination with a virulent 078 Nalidixic acid resistant E. coli (Figures 1 and 2). Seven days post challenge, slight nasal and tracheal colonization was detected in the mutant group.

5           The non-mutant group had slight nasal colonization with moderate colonization of the lower trachea. The unexposed control group had extensive colonization of the nasal and lower trachea. No signs of infection were seen in any of the exposed birds. Both  
10 vaccinated groups prevented the colonization of the virulent E. coli 078 challenge.

Table 6 below is a summary of Figures 1 and 2, but is expressed in mean cumulative colony forming units in the trachea and nasal passages. Mean colony forming  
15 units were calculated from day 4 through day 27 to compare the pre-challenge and post-challenge of the mutant, non-mutant and control (non-vaccinated challenged).

TABLE 6

MEAN CUMULATIVE COLONY FORMING UNITS IN THE  
TRACHEA AND NASAL PASSAGES

TREATMENT	PRE-CHALLENGE <sup>A</sup>		POST-CHALLENGE <sup>B</sup>	
	NASAL	TRACHEA	NASAL	TRACHEA
TS-MUTANT	48.87	5.78	0.17	0.16
NON-MUTANT	8.33	78.44	1.0	36.0
NONE	1.84	1.44	260	232

<sup>A</sup> MEAN CUMULATIVE COLONY FORMING UNITS OF THE MUTANT,  
NON-MUTANT AND CONTROL GROUPS OF THE PRE-CHALLENGE  
PERIOD (DAYS 4-20).

<sup>B</sup> MEAN CUMULATIVE COLONY FORMING UNITS OF THE MUTANT,  
NON-MUTANT AND CONTROL GROUPS OF THE POST CHALLENGE  
PERIOD (DAYS 20-27).

2. 078/V challenge -- As indicated in Table 7 below, the 01a/MP vaccine provided significant protection against 078/V challenge at all three dosage levels when lesion score indices were compared. The 5 01a/MP vaccine provided significant protection at  $10^6$  and  $10^7$  dosage levels when groups were evaluated for total birds remaining normal.

Example 2Live Mutant Ola E. coli Vaccine:  
Preparation and Evaluation of Efficacy in Chickens

5           A. Bacteria Mutant E. coli Vaccine -- E. coli  
Ola/MP MSB 120189. Frozen titer:  $1 \times 10^9$  CFU/ml.

10          B. Chickens -- SPF leghorns, HY-VAC Hatcheries,  
Adel, Iowa. The chicks were received at [one ?] day of  
age and reared in isolation until used for testing at 3  
weeks of age.

15          C. E. coli Challenge -- Virulent E. coli 01a/V  
042990 and E. coli 078/v 120789 Frozen stocks. Titors:  
01a/V =  $3.6 \times 10^9$  CFU/ml and 078/v =  $1.6 \times 10^9$  CFU/ml.

20          At 3 weeks, chickens were stressed by  
eyedrop inoculation with virulent B-41 strain IBV and by  
sinus infection with virulent R strain MG culture. Seven  
days later, birds were injected transnasally with virulent  
E. coli via the nares or through the palatine cleft.  
Seven days later, birds were sacrificed and examined for  
air sac lesions, pericarditis, liver lesions, diarrhea and  
general condition. To aid in evaluating results, signs  
were scored for increasing severity: 1 = normal; 2 = air  
25        sacs cloudy only; 3 = one air sac showing lesions; 4 =  
both air sacs showing lesions; 5 = pericarditis, liver  
lesion, diarrhea; 6 = death.

30          D. Challenge Study -- Chickens in separate  
groups were vaccinated intranasally (IN) with graded  
dosages of  $10^5$ ,  $10^6$ , and  $10^7$  CFU/bird of E. coli vaccine.  
At 3 weeks, vaccinated and control groups were divided  
equally, stressed and challenged with 01a/v or 078/v as  
described.

35          1. 01a/v challenge -- no test. The  
challenge was unable to bring down any of the unvaccinated  
controls.

Example 3Live Mutant 078 E. coli Vaccine:Preparation and Evaluation of Efficacy in Chickens

5           A. Bacterial Mutant E. coli Vaccine - E. coli  
078. Frozen.

B. Chickens - SPF leghorns, HY-VAC Hatcheries, Adel, Iowa. The chicks were received at one day of age and reared in isolation until used in testing at about 3  
10 weeks of age.

C. E. coli Challenge - Virulent E. coli 078. Frozen. Titer:  $1.6 \times 10^9$  CFU/ml. A volume of 0.1 ml was injected into the nasal tract via the nares or the palatine cleft or infectious bronchitis virus IBV/MG-  
15 stressed birds.

D. Challenge Study  
Trial 1 - Chickens were vaccinated intranasally with  $10^6$  CFU of E. coli vaccine. At 3 weeks, the vaccines and controls were stressed by eye drop inoculation of virulent B-41 bronchitis virus and by sinus injection with the virulent "R" strain Mycoplasma fallisepticum. Seven days later, the birds were challenged intranasally with virulent E. coli. After another 7 days the birds were sacrificed and examined for  
25 1) air sac lesions, 2) pericarditis, 3) liver lesions, 4) diarrhea, and 5) general condition. To aid in evaluating results, signs were scored for increasing severity.

30           1     =     normal  
              2     =     air sacs cloudy  
              3     =     one air sac showing lesions  
              4     =     both air sacs showing lesions  
              5     =     pericarditis, liver lesions  
              6     =     death

35 Additional birds were necropsied at 14 and 21 days after prechallenge stress.

Trial 2 - Chickens were vaccinated with graded dosages of E. coli vaccine and then challenged by same methods as  
40 Trial 1.

TABLE 7

EFFICACY OF LIVE MUTANT 01A E. COLI VACCINE IN LEGHORN CHICKENS  
 CHALLENGED INTRANASALLY WITH VIRULENT E. COLI 078  
 AT 4 WEEKS POSTVACCINATION

Intranasal Dosage(1) (CFU/Bird)	Lesion Score(2) (No. Birds)						Birds Protected(3)
	1	2	3	4	5	mean	
10 <sup>7</sup>	10	6	2	0	2	0	1.9 <sup>a</sup> 10/20 <sup>aa</sup>
10 <sup>6</sup>	14	0	0	0	6	0	2.2 <sup>a</sup> 14/20 <sup>aa</sup>
10 <sup>5</sup>	8	4	0	2	6	0	2.8 <sup>a</sup> 8/20 <sup>bb</sup>
Controls	1	5	2	1	3	8	4.2 <sup>b</sup> 1/20 <sup>bb</sup>

- (1) Birds vaccinated at 3 weeks by IN route.
- (2) Birds stressed at 3 weeks PV with IBV and MG and then challenged 7 days later with virulent E. coli. Necropsied 7 days later. See text for lesion score schedule.
- (3) Mean, "a" significantly different than "b." Groups labelled "aa" significantly different than "bb" groups.

TABLE 8

TRIAL 1. Preliminary Vaccination-Challenge Trial With  
Live Mutant 078 E. coli Vaccine in Chickens. Intranasal Challenge,  
With Virulent E. coli 078

	Vaccine Dosage (1) (CFU/Bird)	Lesion Score (2) (No. Birds)						Birds Protected
		1 (negative)	2	3	4	5	6 Mean (most severe)	
<b>10</b>								
		<u>7 Days Postchallenge</u>						
	$10^6$	10	6	1	0	4	1	2.6
	Controls	1	5	2	1	3	8	4.7
<b>15</b>								
		<u>14 Days Postchallenge</u>						
	$10^6$	19	1	0	0	0	0	1.1
	Controls	16	4	0	0	0	0	1.2
<b>20</b>								
		<u>21 Days Postchallenge</u>						
	$10^6$	10	0	0	0	0	0	1.0
	Controls	10	0	0	0	0	0	1.0

25 (1) Birds stressed by eyedrop inoculation with B-41 IBV and intrasinus injection of "R" Strain MG at 7 days before challenge.

(2) Increasing severity of challenge reaction at necropsy.

Trial 1 Results (Table 8) at necropsy at 7 days show significant reduction of challenge signs in vaccinated birds. This group showed an index of 2.6 vs. 4.7 for nonvaccinated controls. Further, 10/20 vaccines 5 remained normal vs. 1/20 controls. Both measurements were significantly different.

Necropsy of additional birds showed rapid clearing of signs at 14 and 21 days. Only 1 vaccine vs. 4 controls showed signs at this time. At 21 days, all birds were 10 negative for air sac signs.

Trial 2 Results (Table 9) showed significant reduction in challenge signs at  $10^6$  and  $10^7$  CFU dosage levels. These birds showed indices of 2.2 and 2.4 vs. 3.8 for the control group. Similarly, 8/20 and 7/20 vaccines in 15 these groups remained free of challenge signs vs. only 1/14 controls. An additional group of vaccines receiving  $10^5$  CFU did not show significant protection. An index of 2.9 and only 3/20 negative birds in this group was not significantly different than the controls.

20

As indicated in Tables 8 and 9, mutant E. coli vaccine 078 in two trials produced significant protection against virulent E. coli challenge administered by respiratory route. Protection was seen as a reduction in 25 air sac and other lesions after challenge. They were best evaluated at 7 days since they disappeared rapidly thereafter, being gone at 21 days. Preferred dosages for protection should be at least  $10^6$  CFU.

TABLE 9

<u>TRIAL 2. Efficacy of Live Mutant 078 E. coli Vaccine in Leghorn Chickens Challenged Intranasally With Virulent E. coli 078 at 4 Weeks Postvaccination</u>								
	Intranasal Vaccine Dosage (CFU/Dose)	Lesion Score (2) (No. Birds)					Birds Protected	
		1 (negative)	2	3	4	5		
10	$10^5$	3	6	4	4	3	0	2.9
	$10^6$	8	6	3	1	2	0	2.2
	$10^7$	7	7	0	3	3	0	2.4
15	Controls	1	1	5	3	1	3	3.8
								1/14

20 (1) Birds stressed by eyedrop inoculation with B-41 IBV and intrasinus injection of "R" Strain MG at 7 days before challenge.

(2) Increasing severity of challenge reaction at necropsy.

International Application No: PCT/ /

**MICROORGANISMS**Optional Sheet in connection with the microorganism referred to on page \_\_\_\_\_, line \_\_\_\_\_ of the description<sup>1</sup>**A. IDENTIFICATION OF DEPOSIT<sup>2</sup>**

Further deposits are identified on an additional sheet  Escherichia coli serotypes 078  
of avian origin, UM/DNL

Name of depositary institution<sup>4</sup>

AMERICAN TYPE CULTURE COLLECTION

Address of depositary institution (including postal code and country)<sup>4</sup>12301 Parklawn Drive  
Rockville, Maryland 20852, USADate of deposit<sup>5</sup>

January 21, 1991

Accession Number<sup>6</sup>

55141

**B. ADDITIONAL INDICATIONS<sup>7</sup>** (leave blank if not applicable). This information is continued on a separate attached sheet **C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE<sup>8</sup>** (if the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS<sup>9</sup>** (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later<sup>9</sup> (Specify the general nature of the indications e.g.  
"Accession Number of Deposit")

E.  This sheet was received with the international application when filed (to be checked by the receiving Office).

*Virginia L. Kelly*  
(Authorized Officer)

The date of receipt (from the applicant) by the International Bureau<sup>10</sup>

was

(Authorized Officer)

(January 1985)



**WHAT IS CLAIMED IS:**

1. A vaccine comprising an immunogenic amount of a live temperature sensitive mutant of Escherichia coli dispersed in a physiologically acceptable non-toxic liquid vehicle, which amount is effective to immunize a susceptible domestic fowl against colibacillosis, said mutant exhibiting growth at 32°C but not at 41°C and having a reversion frequency of less than about  $1 \times 10^{-8}$ .
2. The vaccine of claim 1 wherein said temperature sensitive mutant is a mutant of E. coli serotype 078.
3. The vaccine of claim 1 wherein said temperature sensitive mutant is a mutant of E. coli serotype 01a.
4. The vaccine of claim 1 wherein said temperature sensitive mutant is a mutant of E. coli serotype 02a.
5. The vaccine of claim 1 wherein the immunogenic live temperature sensitive mutant colonizes the upper nasal mucosa of said domestic fowl for at least 20 days post inoculation.
6. The vaccine of claim 1 wherein said mutant has a reversion frequency of less than  $1 \times 10^{-9}$ .
7. The vaccine of claim 1 wherein said domestic fowl is a turkey.
8. The vaccine of claim 1 wherein said domestic fowl is a chicken.
9. A method to immunize a domestic fowl against colibacillosis comprising administering to said

domestic fowl an effective amount of the vaccine of claim 1.

10. The method of claim 9 wherein the vaccine is administered by aerosol.
11. The method of claim 9 wherein the vaccine is administered orally.
12. A method for obtaining a temperature sensitive mutant of Escherichia coli capable of colonizing the nasal mucosa of a domestic fowl, comprising the steps of:
  - (a) treating a culture of Escherichia coli with a mutagen and a protein synthesis inhibitor, said mutagen and protein synthesis inhibitor being employed in an amount sufficient to maximize mutation and minimize reversion frequency;
  - (b) selecting said culture mutants exhibiting growth at 32°C but not at 41°C and having a reversion frequency of less than  $1 \times 10^{-8}$ .
13. The method of claim 12 wherein said mutagen is N-methyl-N-nitro-N-nitrosoguanidine.
14. The method of claim 12 wherein said protein synthesis inhibitor is chloramphenicol.
15. The method of claim 13 wherein said culture is treated with about 25 µg/ml chloramphenicol.
16. A method for obtaining a stable temperature sensitive mutant of Escherichia coli capable of colonizing the nasal mucosa and enhancing immunological resistance to colibacillosis in domestic fowl, comprising the steps of:
  - (a) treating a culture of a parental strain of E. coli with amounts of a mutagen and protein

- synthesis inhibitor sufficient to produce temperature sensitive mutants having a reversion frequency of less than  $1 \times 10^{-9}$ ;
- (b) incubating a sample of said treated culture on agar plates at about 32°C for a period of time sufficient to produce colony growth;
  - (c) employing replica plating to transfer colonies onto agar plates incubated at 32°C and 41°C;
  - (d) selecting mutants based on smaller colony morphology than the parental strain and inhibited growth at 41°C;
  - (e) growing said selected mutants at 32°C and 41°C to determine mutant stability against reversion; and
  - (f) selecting a mutant having a reversion frequency of less than  $1 \times 10^{-9}$ ;
17. The method of claim 16 wherein said culture is treated with about 25  $\mu\text{g}/\text{ml}$  of chloramphenicol.
18. The method of claim 17 wherein said culture is treated with about 1000  $\mu\text{g}/\text{ml}$  N-nitro-N-nitrosoguanidine.



2/2




FIG. 3

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/00166

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>3</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5): A 61K 39/02, A 01N 63/00 US CL : 424/92, 424/93		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>4</sup>		
Classification System	Classification Symbols	
U.S.	424/92, 424/93	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>5</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>14</sup></b>		
Category <sup>6</sup>	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
Y	American Society for Microbiology Abstracts, issued 13-17 May 1990, Heeg et al, "Development of a Live Vaccine to Prevent Air Sacculitis in Chickens," see abstract no. E-4.	1-11
X	39th North Central Avian Disease Conference, issued 21-22 September 1988, Emery et al, "Development of a Temperature Sensitive Mutant of <u>E. coli</u> for The Control of Colibacillosis in Turkeys", pages 32-34, see entire document.	1-18
Y	Biochemical And Biophysical Research Communications, Volume 18, No. 5-6, issued 1965, Adelberg et al, "Optimal Conditions For Mutagenesis By N-Methyl-N'-Nitro-N-Nitrosoguanidine In <u>Escherichia coli</u> K12", pages 788-795, see entire article.	12-18
Y	Journal of Bacteriology, Volume 136, No. 1, issued October 1978, Sklar, "Enhancement of Nitrosoguanidine Mutagenesis by Chloramphenicol in <u>Escherichia coli</u> K-12" pages 460-462, see entire article.	14-17
<p><sup>*</sup> Special categories of cited documents:<sup>15</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search <sup>2</sup>  17 MARCH 1992	Date of Mailing of the International Search Report <sup>2</sup>  31 MAR 1992	
International Searching Authority <sup>1</sup>  ISA/US	Signature of Authorized Officer <sup>20</sup>  H. F. Sidberry <i>J. Marie Jr.</i>	

**FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET**

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET		
X	Conference of Research Workers in Animal Diseases , issued 14-15 November 1988, Nagoya; "The Use of Temperature Sensitive Mutants of <u>Escherichia coli</u> for The Control of Colibacillosis in Turkeys", see abstract no. 80.	1-13,18
<b>V. <input type="checkbox"/> OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup></b>		
This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:		
1. <input type="checkbox"/> Claim numbers „, because they relate to subject matter (1) not required to be searched by this Authority, namely:		
2. <input type="checkbox"/> Claim numbers „, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out (1), specifically:		
3. <input type="checkbox"/> Claim numbers „, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).		
<b>VI. <input type="checkbox"/> OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup></b>		
This International Searching Authority found multiple inventions in this international application as follows:		
1. <input type="checkbox"/> As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.		
2. <input type="checkbox"/> As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:		
3. <input type="checkbox"/> No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:		
4. <input type="checkbox"/> As all searchable claims could be searched without effort justifying an additional fee, the International Search Authority did not invite payment of any additional fee.		
Remark on protest		
<input type="checkbox"/> The additional search fees were accompanied by applicant's protest.		
<input type="checkbox"/> No protest accompanied the payment of additional search fees.		

